R&D Management

Hanmi Pharmaceutical R&D Vision

In December 2025, Hanmi Group's R&D Center, responsible for its future value, announced a strategy to lead a healthy aging era under the vision of ‘Shaping the Future of Aging’.
Hanmi Pharmaceutical is demonstrating its R&D capabilities through accelerating clinical development of innovative drug pipelines, securing First-in-Class drugs, and initiating numerous next-generation oncology projects based on new modalities. It is also excelling in academic achievements alongside clinical progress in key obesity/metabolic disease treatments.
Hanmi Pharmaceutical will make 2030 a period of new leaps forward, expanding beyond research into oncology, obesity, and metabolic diseases to anti-aging and reverse-aging research.

1. Global-level R&D Infrastructure and Technological Capabilities

Leading the next-generation drug paradigm by internalizing new technologies such as AI, BI/Omics

2. Metabolic to Longevity Leading the Anti-aging / Rejuvenation Field

Through the advancement of the H.O.P project, we will transform the next-generation obesity treatment market into an anti-aging/Longevity market.

Hanmi Pharmaceutical's Aging Market Approach Strategy

3. Open Innovation Continuous creation of FIC innovative new drugs

R&D Investment

Hanmi Pharmaceutical is actively practicing R&D management to create 'global innovative new drugs'. Including investments in innovative drug research fields such as new drug development, biopharmaceuticals, and synthetic new drugs, as well as production facilities essential for product commercialization, its total R&D investment over the past decade amounts to KRW 2.9078 trillion. Hanmi Pharmaceutical will continue to make utmost efforts to realize a pharmaceutical powerhouse through sustained R&D investment.

R&D Personnel

Hanmi Pharmaceutical operates 5 R&D centers in Korea, where 489 researchers are dedicated to R&D. Including the Beijing Hanmi Pharmaceutical research institute located in Beijing, the total number of researchers is 670, representing 17.3% of the total workforce.

2025 Hanmi Pharmaceutical R&D Personnel Status

Annual Hanmi Pharmaceutical R&D Personnel Status²⁾

R&D Network

Hanmi Pharmaceutical's R&D network is centered around the Hanmi Pharmaceutical R&D Center in Dongtan, Gyeonggi Province. It also includes the Seoul Research Center located at the Seoul headquarters, the Formulation Research Center affiliated with the Paltan Smart Plant, the Bio Process Research Center within the Pyeongtaek Bio Plant, and research institutes within its subsidiaries, Beijing Hanmi Pharmaceutical and Hanmi Fine Chemical. This network establishes an optimal research environment to facilitate rapid development and commercialization of substances in the research phase.

Core R&D Technologies

Based on advanced technology and research, Hanmi Pharmaceutical creates sustainable R&D and innovations unprecedented in the world. Currently, Hanmi Pharmaceutical possesses technologies such as long-acting biologics enabled by its LAPSCOVERY platform and bispecific antibody technologies. It is also focusing on developing improved and complex new drugs to enhance patients' quality of life. In the future, Hanmi Pharmaceutical will strive for sustainable development by discovering new modalities such as 'Antibody-Drug Conjugates (ADCs),' 'Cell and Gene Therapies,' 'mRNA-based Therapies,' and 'Targeted Protein Degraders.'

Key Research Areas

Obesity/Metabolism

Obesity is known to be a cause of major metabolic syndromes such as diabetes, hypertension, cardiovascular diseases, and fatty liver disease. The World Health Organization (WHO) defines obesity as the '21st-century epidemic' that modern society must address. Based on expertise and R&D capabilities in incretin science, we are conducting research to build a customized, full-cycle obesity management portfolio (H.O.P: Hanmi Obesity Pipeline) that encompasses differentiated obesity prevention, treatment, and high-quality weight management, utilizing peptides, proteins, formulation technology, and digital therapeutics.

Targeted + Immuno-oncology

Cancer is one of the most serious diseases affecting humanity and a major cause of death worldwide. Hanmi Pharmaceutical is dedicated to innovative new drug research to overcome resistance to existing drugs and achieve the ultimate goal of 'conquering cancer.' We are conducting research to enhance drug efficacy and expand indications through various combination therapies, including gene mutation-targeted cancer therapies, immuno-oncology drugs, and bispecific antibodies. Furthermore, in response to the accelerating era of digital transformation, we are actively promoting open innovation utilizing artificial intelligence to expand our pipeline.

Rare Diseases

Hanmi Pharmaceutical's management philosophy of 'Respect for Human Beings' and 'Value Creation' shines brightly, especially in the field of 'rare diseases,' among various new drug development areas. This also represents Hanmi Pharmaceutical's reason for existence: to contribute to a better life for humanity. In accordance with the management philosophy of its founder, the late Chairman Lim Sung Ki, who famously stated, "New drug development is social contribution," Hanmi Pharmaceutical is fully committed to developing innovative new drugs that can offer hope to patients worldwide suffering from rare diseases.

Pipeline

Securing and Strengthening Intellectual Property through R&D

The pharmaceutical industry is a national industry in South Korea that aims to contribute to the healthy lives of humanity. In particular, the status of pharmaceutical patent holdings serves as a quantitative measure and indicator, becoming another criterion for evaluating a company's R&D capabilities. Hanmi Pharmaceutical will continue its efforts to become a pharmaceutical powerhouse based on excellent intellectual property rights.

Hanmi Pharmaceutical Domestic and International Patent Application Status¹⁾ (As of Dec. 31, 2025)

Domestic Pharmaceutical Patent Holdings Status (As of Dec. 31, 2025)

Number of Domestic Patent applications²⁾³⁾

Number of Overseas Patent applications²⁾³⁾⁴⁾

2) Domestic and international patent applications are published 1 year and 6 months after the filing date, thus the period from 2019 to 2024 was investigated.
3) Source: KIPRIS, Patent Search Database (WipsON)
4) PCT: Patent Cooperation Treaty

Contribution to the Fiscal Soundness of the National Health Insurance through Improved Combination New Drugs

The National Health Insurance, which underpins South Korea's healthcare policy and serves as a foundation for improving public health and quality of life, emphasizes the critical importance of securing its financial soundness. Hanmi Pharmaceutical, leveraging its global-standard R&D capabilities, contributes to the financial stability of the National Health Insurance by providing incrementally improved combination new drugs. Even when limited to six key products by 2025, it is estimated to have contributed to health insurance fiscal savings of up to KRW 94.3 billion.